Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 774
- Registration Number
- NCT04019873
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University Hospital Virgen de las Nieves
- Target Recruit Count
- 88
- Registration Number
- NCT04002323
- Locations
- 🇪🇸
Hospital Universitario Virgen de Las Nieves, Granada, Andalucía, Spain
🇪🇸Hospital Clínico Universitario "Virgen de la Arrixaca", El Palmar, Región De Murcia, Spain
🇪🇸Hospital Reina Sofía, Murcia, Región De Murcia, Spain
Nucleosides And Darunavir/Dolutegravir In Africa
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 465
- Registration Number
- NCT03988452
- Locations
- 🇺🇬
Infectious Diseases Institute, Kampala, Uganda
Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 1506
- Registration Number
- NCT03870438
- Locations
- 🇿🇲
Chaisa, Lusaka, Zambia
🇿🇲Chilenje Level 1 hospital, Lusaka, Zambia
🇧🇫CSPS and CMA of Baskuy and Boulmiougou districts, Ouagadougou, Burkina Faso
Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 97
- Registration Number
- NCT03869944
- Locations
- 🇧🇫
Paulin Fao, Bobo-Dioulasso, Burkina Faso
Body Composition Sub-study of the D2EFT Trial
- Conditions
- HIV Infections
- Interventions
- Drug: TDF 300 MG Oral TabletDrug: N(t)RTIsDrug: FTC 200 MG Oral Cap
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 155
- Registration Number
- NCT03675815
- Locations
- 🇿🇦
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, Johannesburg, South Africa
🇿🇦Clinical HIV Research Unit, Helen Joseph Hospital, Westdene, Johannesburg, South Africa
🇿🇦Desmond Tutu HIV Foundation, Cape Town, South Africa
Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2020-07-07
- Target Recruit Count
- 41
- Registration Number
- NCT03539224
- Locations
- 🇪🇸
Hospital 12 de Octubre, Madrid, Spain
🇪🇸Hospital Universitario La Paz, Madrid, Spain
The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2022-05-12
- Target Recruit Count
- 109
- Registration Number
- NCT03528941
- Locations
- 🇮🇹
AOU Arcispedale S.Anna - UOC Ematologia e fisiopatologia della coagulazione, Cona, Ferrara, Italy
🇮🇹AOU Maggiore della Carità di Novara - SCDU Ematologia, Novara, Italy
🇮🇹AOU Città della Salute e della Scienza, Ospedale S.Giovanni Battista Molinette - SC Ematologia, Torino, Italy
Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
- Conditions
- HIV-1-infectionSolid Organ Transplant
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Target Recruit Count
- 20
- Registration Number
- NCT03360682
- Locations
- 🇪🇸
Hospital Clínico y provincial de Barcelona, Barcelona, Spain
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
- Conditions
- HIV SeropositivityHIV InfectionsHIV-1-infection
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Judit Pich
- Target Recruit Count
- 17
- Registration Number
- NCT03333083
- Locations
- 🇪🇸
Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.